First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment.
Yun KimShi-Ra LeeSang Won LeePublished in: Alimentary pharmacology & therapeutics (2023)
The results of this study suggest that J2H-1702 could be developed as an effective therapeutic option for NASH.